Heterogeneity of Large Cell Carcinoma of the Lung
Open Access
- 1 November 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 136 (5) , 773-782
Abstract
Large cell carcinomas (LCCs) of the lung are heterogeneous and may be of different cell lineages. We analyzed 56 surgically resected lung tumors classified as LCC on the basis of pure morphologic grounds, using a panel of immunophenotypic markers (adenocarcinoma [ADC]-specific, thyroid transcription factor-1, cytokeratin 7, and napsin A; squamous cell carcinoma [SQCC]–specific, p63, cytokeratin 5, desmocollin 3, and Δnp63) and the quantitative analysis of microRNA-205 (microRNA sample score [mRSS]). Based on immunoprofiles 19 (34%) of the cases were reclassified as ADC and 14 (25%) as SQCC; 23 (41%) of the cases were unclassifiable. Of these 23 cases, 18 were classified as ADC and 5 as SQCC according to the mRSS. Our data show that an extended panel of immunohistochemical markers can reclassify around 60% of LCCs as ADC or SQCC. However, a relevant percentage of LCCs may escape convincing immunohistochemical classification, and mRSS could be used for further typing, but its clinical relevance needs further confirmation.Keywords
This publication has 35 references indexed in Scilit:
- Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical SpecimensJournal of Thoracic Oncology, 2011
- miR-205 Expression Levels in Nonsmall Cell Lung CancerDo Not Always Distinguish Adenocarcinomas From Squamous Cell CarcinomasAmerican Journal of Surgical Pathology, 2011
- Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell TypesClinical Cancer Research, 2010
- The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the LungPLOS ONE, 2010
- Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival PredictionPLOS ONE, 2010
- The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de‐stained bronchial lavage cytological smearsCytopathology, 2010
- Histology Matters: Individualizing Treatment in Non-Small Cell Lung CancerThe Oncologist, 2010
- Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized TreatmentsInternational Journal of Surgical Pathology, 2009
- Expression signatures in lung cancer reveal a profile for EGFR ‐mutant tumours and identify selective PIK3CA overexpression by gene amplificationThe Journal of Pathology, 2008
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004